Previous 10 | Next 10 |
2023-03-09 16:20:59 ET Cytosorbents press release ( NASDAQ: CTSO ): FY GAAP EPS of -$0.75 beats by $0.14 . Revenue of $29.36M (-26.8% Y/Y) misses by $4.69M . Grant Income, was $9.4 million versus $10.8 million in Q4 2021, a decrease of 13% Product Sales wer...
Pivotal U.S. and Canada STAR-T Trial enrollment passes halfway mark. Positive sales momentum from Q4 2022 continues in Q1 2023 to date, with expectation of sales growth in 2023 PRINCETON, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in...
2023-03-08 17:35:28 ET Major earnings expected after the bell on Thursday include: Oracle corporation ( ORCL ) DocuSign ( DOCU ) Wheaton Precious Metals Corp. ( WPM ) Bionano Genomics ( BNGO ) Ulta Beauty (ULTA0) For further details see: ...
PRINCETON, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that hemoadsorption of antithrombotic drugs in cardioth...
CytoSorbents to Present at the Cowen 43rd Annual Health Care Conference PR Newswire PRINCETON , N.J. , Feb. 27, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care un...
CytoSorbents to Report Fiscal 2022 Operating and Financial Results PR Newswire MONMOUTH JUNCTION, N.J. , Feb. 24, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit...
Medical device company CytoSorbents ( NASDAQ: CTSO ) reported on Tuesday its preliminary results, expecting total revenue of ~$34.7M ( consensus : $33.57M) for 2022. The company generated $43.2M in 2021 and $24.9M in pre-pandemic 2019. Q4 revenue is estimated at ~$9.4M vs. $8....
CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2022 Revenue PR Newswire Cumulative CytoSorb treatments surpassed 195,000. Q4 2022 product sales rebounded from Q3 2022 low. Adjusted for constant currency, Core non-COVID 2022 product ...
MedTech firm CytoSorbents Corporation ( NASDAQ: CTSO ) announced Monday that Health Canada approved patient enrollment in the country for its pivotal STAR-T trial, which tests the company's DrugSorb-ATR antithrombotic removal system. The FDA-approved trial, known as Safe and Timely An...
CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial PR Newswire PRINCETON, N.J. , Jan. 23, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensiv...
News, Short Squeeze, Breakout and More Instantly...
CytoSorbents Corporation Company Name:
CTSO Stock Symbol:
NASDAQ Market:
CytoSorbents Corporation Website:
PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces that it has regained comp...
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, is proud to announce the launch of ...
PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces it will present...